Key facts
- This page summarizes Jeffrey L. Edwards's Form 4 filing for KYNTRA BIO, INC. (KYNB).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2026, 19:42.
Jeffrey L. Edwards - 12 Jun 2026 Form 4 Insider Report for KYNTRA BIO, INC. (KYNB)
- Reporting relationship
- Director
- Issuer ticker
- KYNB
- Reported as of
- 12 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2026, 19:42:22 UTC
- Prior SEC filing
- 23 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ John Alden, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey L. Edwards filed Form 4 for KYNTRA BIO, INC. (KYNB) on 17 Jun 2026.
Change
- Previous filing in this sequence was filed on 23 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001190642
Primary reporting owner
EDWARDS JEFFREY L
- Relationship
- Director
- Address
- C/O KYNTRA BIO, INC., 350 BAY STREET, SUITE 110, #6009, SAN FRANCISCO
- Signature
- /s/ John Alden, Attorney-in-Fact
- Signature date
- 17 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KYNB
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +7,000
- Change %
- Price
- $0.000000*
- Shares after
- 7,000
- Date
- 12 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,000
- Exercise price
- $7.13
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant.